Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Ondra Health vs Gala Health

Two GLP-1 desks, one scoreboard. We put Ondra Health and Gala Health head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 8 · Grade B+

Ondra Health

Visit Ondra Health Full brief →
vs
No. 12 · Grade B

Gala Health

Visit Gala Health Full brief →

The verdict

Ondra Health takes this head-to-head.

Ondra Health scores 87 to 86 on our six-factor Brief Score — A rare combination of a rock-bottom $93 semaglutide, brand-name access, LegitScript certification and all-50-state reach.

That doesn't make Gala Health a bad call — it's best for readers who want a low compounded-tirzepatide starting price in all 50 states but like knowing a brand-name ozempic route exists if they ever switch — and who value a menopause/hrt program alongside the glp-1. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
88
85
Supply Reliability
86
84
Transparency
88
86
Access Breadth
90
90
Clinical Oversight
88
85
Track Record
82
82
Ondra HealthBrief Score 87 · 86Gala Health

Price, coverage & the tracker

Ondra HealthGala Health
Brief Score87/100 (B+)86/100 (B)
Semaglutide$93/moNot disclosed
Tirzepatide$166/mo$179/mo
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableStableprice stable

Ondra Health: $93 sema / $166 tirz — the lowest accredited nationwide line we track; brand access + LegitScript.

Gala Health: Low compounded-tirz entry unchanged this cycle; the desk pairs it with a brand-name lane most compounding-only shops don't offer.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.